Annual Information Update

RNS Number : 1264F

Hikma Pharmaceuticals Plc

17 April 2014

 



Annual Information Update

London, 17 April 2014.  In accordance with Prospectus Rule 5.2, Hikma Pharmaceuticals PLC ("Hikma" or "the Company") (LSE: HIK) sets out below a summary of the information which has been published or made available to the public over the period. The information referred to in this Update was up to date at the time the information was published, but some information may now be out of date.

Stock Exchange Announcements

Announcements made by the Company via RNS, a Regulatory Information Service, may be viewed and downloaded from the Company's market news section on the London Stock Exchange website at (http://www.londonstockexchange.com/prices-and-news/stocks/stocks-and-prices.htm) or from the press releases page on the Company's website at (http://www.hikma.com/investorrelations/rns/). The Stock Exchange announcements made during the period were:

Date	Headline
14/04/2014	Director/PDMR Shareholding
07/04/2014	Blocklisting Interim Review
07/04/2014	Total Voting Rights
02/04/2014	Successful resolution to US FDA warning letter
24/03/2014	Director/PDMR Shareholding
12/03/2014	Directorate Change
12/03/2014	Final Results
27/02/2014	Notification of major interests in shares
21/02/2014	Block Listing of Shares
14/02/2014	Trading Statement
11/02/2014	Directorate Change
30/12/2013	Director/PDMR Shareholding
20/12/2013	Director/PDMR Shareholding
20/12/2013	Director/PDMR Shareholding
16/12/2013	Total Voting Rights
13/12/2013	Holding(s) in Company
20/11/2013	Re Agreement
11/11/2013	Director/PDMR Shareholding
08/11/2013	Director/PDMR Shareholding
08/11/2013	Interim Management Statement
25/10/2013	Director/PDMR Shareholding
23/10/2013	Holding(s) in Company
18/10/2013	Director/PDMR Shareholding
04/10/2013	Dividend Declaration
01/10/2013	Blocklisting Interim Review
01/10/2013	Total Voting Rights
18/09/2013	Hikma entering Ethiopian pharmaceutical market
02/09/2013	Transaction in Own Shares
29/08/2013	Transaction in Own Shares
21/08/2013	Interim Results
31/07/2013	Director/PDMR Shareholding
19/07/2013	Total Voting Rights
08/07/2013	Trading Statement
05/07/2013	Holding(s) in Company
01/07/2013	Signing of Exclusive Agreement with Theravance
20/06/2013	Director/PDMR Shareholding
03/06/2013	Total Voting Rights
28/05/2013	Holding(s) in Company
23/05/2013	Director/PDMR Shareholding
21/05/2013	Director/PDMR Shareholding
20/05/2013	Director/PDMR Shareholding
16/05/2013	Result of AGM
16/05/2013	Interim Management Statement
10/05/2013	Director/PDMR Shareholding
02/05/2013	Director/PDMR Shareholding
23/04/2013	Director/PDMR Shareholding
18/04/2013	Director/PDMR Shareholding
17/04/2013	Hikma update on global Injectables business
10/04/2013	Annual Financial Report

All of the above announcements were also made by the Company via the Nasdaq Dubai stock exchange CANDI system.  These announcements may be viewed and downloaded from the Nasdaq Dubai website (www.candi.nasdaq.com). 

Documents filed with the Financial Services Authority

The Company has filed the following documents with the Financial Services Authority ("FSA") visa the National Storage Mechanism over the previous 12 months.  These documents are available at http://www.hemscott.com/nsm.do or at the Company's registered office.

Date	Document
10 April 2014	Annual Report and Accounts 2013
10 April 2014	Notice of 2014 Annual General Meeting
10 April 2014	Proxy forms for the 2014 Annual General Meeting
10 April 2013	Annual Report and Accounts 2012
10 April 2013	Notice of 2013 Annual General Meeting
10 April 2013	Proxy forms for the 2013 Annual General Meeting

Documents filed with Companies House

The Company submitted filings to the Registrar of Companies in England and Wales as detailed in the table below. 

Date Filed	Form	Description
05/04/2013	SH01	Statement of Capital GBP 19,748,436.90
24/05/2013	RES10	Authorised Allotment of Shares and Debentures
02/07/2013	AA	Group of Companies' Accounts made up to 31/12/12
19/07/2013	SH01	Statement of Capital GBP 19,794,212.80
11/09/2013	AR01	Annual Return - No Member List
25/09/2013	MR01	Registration of a Charge / Charge Code 055579340002
07/10/2013	SH03	Return of Purchase of Own Shares - Treasury Capital GBP 21,000
10/10/2013	SH01	Statement of Capital GBP 19,796,502.80
07/04/2014	SH01	Statement of Capital GBP 19,815,699.70
07/04/2014	SH01	Statement of Capital GBP 19,815,699.70

Copies of all these documents may be obtained from Companies House, Crown Way, Maindy, Cardiff CF14 3UZ or, if you are a registered user, they may be viewed and downloaded using Companies House "Webcheck" at www.companieshouse.gov.uk.

Further Information

Copies of all documents can be obtained from the Company at the registered office which is located at 13 Hanover Square, London W1S 1HW.

Peter Speirs

Company Secretary
17 April 2014

- ENDS -

Enquiries:

Hikma Pharmaceuticals PLC
Peter Speirs Company Secretary	[phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million. 

 

END

 

 

AIUEDLFFZZFZBBF